Dong-E-Jiao signs partnership for pharmaceutical industry investment fund

Dong-E-Jiao announced the signing of the partnership agreement for the Hu-Run (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) on October 28, 2025. This follows the board approval on July 17, 2025, to participate in the fund, which aims to support the company's strategic development by investing in the health and wellness sector. The fund's total scale is RMB1 billion.

Dong-E-Jiao will contribute RMB60 million in proprietary funds to the fund, securing a 6% ownership stake. This investment is aligned with the company's strategy to optimize its resource acquisition and allocation capabilities, diversify investment tools, and build a pipeline of high-quality projects for future growth, without adversely affecting its financial position or operational results. The company emphasizes that this investment will not lead to control or significant influence over the fund, nor will it result in new consolidated subsidiaries.

The company will continue to monitor the fund's operations and manage potential risks, including those related to market conditions, management, liquidity, and investment returns. Further disclosures will be made in accordance with regulatory requirements.